Publication details

Roční zkušenosti s Macugenem v léčbě vlhké formy VPMD

Title in English One year experience with Macugen in treatment of wet form of AMD
Authors

KOLÁŘ Petr

Year of publication 2008
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description Pegaptanib (Macugen) is registrated for treatment of wet age related macular degeneration from August 2007. Pegaptanib is de facto first agent from group of antagonists of vascular endothelial growth factors. It inhibits specific isoform VEGF165.

You are running an old browser version. We recommend updating your browser to its latest version.

More info